OT mobile menu

Search form


Lung Cancer Targets

Study Identifies How Lung Tumors Acquire Immunotherapy Resistance

NSCLC can acquire resistance to immune checkpoint blockade agents through evolutionary culling of tumor clones harboring the mutations for cell surface neoantigens that are recognized by patients’ immune T cells. Image © Tashatuvango/ Shutterstock.com

Image © koya979 / Shutterstock.com

Lung Cancer Targets

A subpopulation of T cells called tissue resident memory cells may be able to determine which cancer patients whose immune system mounts an effective anti-tumor response

The FDA has approved dabrafenib in combination with trametinib for the treatment of BRAF V600E mutated non-small cell lung cancer.

Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.

In this podcast interview, Dr. Hossein Borghaei discusses some of the latest science presented at ASCO that focuses on immunotherapy in lung cancer.

Dr. Karen Reckamp talks about ways to incorporate biomarkers for the treatment of lung cancer with immunotherapy into clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.

A new study has found that high tumor mutation load is associated with older age, absence of oncogenic mutations, and presence of tumor suppressor gene mutations.

Higher doses of the kinase inhibitor brigatinib as second-line therapy for ALK-positive non–small-cell lung cancer may be an option for some patients.


Subscribe to Lung Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.